Last reviewed · How we verify
Methylaminolevulinate cream
Methylaminolevulinate cream is a marketed product developed by the Joint Authority for Päijät-Häme Social and Health Care, with a key composition patent expiring in 2028. The drug's market position is bolstered by its unique mechanism of action, though specific details are not provided. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Methylaminolevulinate cream |
|---|---|
| Also known as | Metvix, Galderma, L01X D03, MAL |
| Sponsor | Joint Authority for Päijät-Häme Social and Health Care |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Photodynamic Therapy (PDT) Effect on Large Surface Photodamaged Skin (NA)
- Potential Impact of Patient Vitamin D Status in AK Response to MAL-PDT (NA)
- Superficial Basal Cell Cancer's Photodynamic Therapy: Comparing Three Photosensitizers: HAL and BF-200 ALA Versus MAL (PHASE1, PHASE2)
- Efficacy and Safety of Treatment of Actinic Keratoses With Photodynamic Therapy Between MAL Cream and ALA Gel (PHASE4)
- Photodynamic Therapy Using Methyl-5-Aminolevulinate Hydrochloride Cream in Determining Pain Threshold in Patients With Skin Cancer (PHASE1)
- Short Incubation Methylaminolevulinate Photodynamic Therapy Without Occlusion (PHASE3)
- Safety and Efficacy Study of Topical Methyaminlevulinate (MAL) in Subjects With Facial Acne (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: